Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
Sponsors
Alcon Research
Conditions
Allergic Conjunctivitis
Phase 3
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
CompletedNCT00331500
Start: 2006-04-18End: 2006-07-27Updated: 2017-08-14
Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects
CompletedNCT00987272
Start: 2009-10-31End: 2009-11-30Updated: 2014-07-31
An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis
CompletedNCT01037179
Start: 2010-02-28End: 2010-05-31Updated: 2014-08-04
Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
CompletedNCT01479374
Start: 2012-01-31End: 2012-03-31Updated: 2013-06-04
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
CompletedNCT01743027
Start: 2013-01-31End: 2013-07-31Updated: 2014-08-11
Phase 4
A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis
CompletedNCT01272089
Start: 2011-05-31End: 2011-12-31Updated: 2012-09-18
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
CompletedNCT01697969
Start: 2012-09-30End: 2013-07-31Updated: 2014-08-18